Lucia Santa Maria de la Parra

Dr. Lucia Santa Maria de la Parra

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in Inorganic Chemistry
Verified
Journal Article
Closed access
LPLucia Santa Maria de la Parra
Lucia Santa Maria de la Parra
ARadolfo I barros romo
adolfo I barros romo
JRJoaquín Rodríguez-López
Joaquín Rodríguez-López
ONOtaciro R. Nascimento
Otaciro R. Nascimento
GEGustavo A. Echeverría
Gustavo A. Echeverría
ILIgnacio E. León
Ignacio E. León

17 March 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LPLucia Santa Maria de la Parra
Lucia Santa Maria de la Parra
MAMatias Hernan Assandri
Matias Hernan Assandri
LSLuisina María Solernó
Luisina María Solernó
MSMaria de los Angeles Serradell
Maria de los Angeles Serradell
DADaniel F. Alonso
Daniel F. Alonso
Ignacio E. LeónIgnacio E. León
Ignacio E. León
Introduction: Osteosarcoma (OS) is the most common primary malignant bone tumor in children and young adults, with poor prognosis due to relapse, metastasis, and chemoresistance. The search for novel metal-based therapeutics has highlighted copper complexes as promising candidates. Here, we report the in vitro and in vivo antitumor activity of a tetranuclear Cu(II)-hydrazone complex (Cu4L4) derived from (E)-5-chloro-N′-(2-hydroxy-3-methoxybenzylidene)thiophene-2-carbohydrazide. Results: Cytotoxic assays on MG-63 OS cells revealed potent activity with an IC50 of 0.50 ± 0.04 µM, significantly surpassing its free ligand (IC50 = 13.9 ± 1.6 µM) and cisplatin (IC50 = 39.0 ± 1.8 µM). This tetranuclear complex outperforms mononuclear Cu-hydrazones analogs (e.g., 4-fold vs. CuHL1, 2-fold vs. CuHL2, 5-fold vs. CuHL3, 17-fold vs. CuHL4,), and Cu4L4 also exhibits reduced clonogenic survival, induces reactive oxygen species production, and promotes late apoptosis as a main mechanism, being the main mechanism of action involved in anticancer activity. In multicellular tumor spheroids, the complex maintained strong cytotoxicity (IC50 = 4.11 ± 0.12 µM), impaired spheroid integrity, and markedly inhibited cell migration at sub-IC50 concentrations. The tetranuclear architecture confers markedly enhanced antitumor activity relative to the corresponding mononuclear Cu–hydrazone complexes (e.g., 2-fold vs. CuHL1, 4-fold vs. CuHL2, 2-fold vs. CuHL3). In a xenograft model, sustained administration of Cu4L4 (2 mg/kg, i.p., twice weekly) inhibited tumor growth by 43.6%, reduced mitotic index, and increased necrotic area without significant systemic toxicity. Conclusions: Overall, Cu4L4 displayed potent and selective antitumor activity against OS cells in 2D, 3D, and in vivo models, underscoring copper–hydrazone complexes as promising scaffolds for the development of new therapies against OS.

16 February 2024 in ChemistrySelect
Verified
Journal Article
Closed access
TMTatiana Muñoz‐Castiblanco
Tatiana Muñoz‐Castiblanco
LPLucia Santa Maria de la Parra
Lucia Santa Maria de la Parra
ECEhidy Rocio Peña Cañón
Ehidy Rocio Peña Cañón
KMKelly Muñoz‐Losada
Kelly Muñoz‐Losada
JMJuan Camilo Mejía-Giraldo
Juan Camilo Mejía-Giraldo
MPMiguel A Puertas‐Mejía
Miguel A Puertas‐Mejía